Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

CCR4+low-density neutrophils define a novel immunosuppressive subset associated with breast cancer progression and early mortality

Bruna F. Correia D. Grosa R. Salvador T. Martins M. Vitorino Jorge M. Mendes Andreia Lopes Marta Parreira Beatriz Martins Guilherme Vilhais M. Marques Maria Gabriela Gasparinho Sofia Critovão-Ferreira D. P. Saraiva Nídia de Sousa S. Braga A. Jacinto M. G. Cabral
Sep 2026 · bioRxiv · 0 citations · 58 references
Biology

TL;DR

A distinct neutrophil population that actively contributes to immune escape and tumor progression is revealed, establishing CCR4+LDN as a minimally invasive real-time biomarker of disease course and treatment response, and as a promising target for neutrophil-directed therapies in BC.

DOI Semantic Scholar
Read PDF

Similar papers

Review Open access Sep 2026

Decoding Low-Density Neutrophils in Breast and Lung Cancer: From Bystanders to Drivers.

Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils (LDNs) have emerged as a clinically relevant population in oncology due to th...

T. Martins, R. Salvador, B. Correia et al. · 0 citations
Open access Sep 2026

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

ABSTRACT High tumor burden is associated with poorer immunotherapy responses compared to low burden, yet the systemic mechanisms driving this impairment and strategies to reverse it remain unclear. We demonstrate that tumors with higher malignancy or stages exert a more pronounced suppression on systemic antitumor immu...

Ji Wang, Xin-Yu Tang, Ze-Ju Li et al. · 0 citations
Review Open access Oct 2026

Tumor-associated macrophages in glioblastoma: implications for immunotherapy

Glioblastoma, IDH-wildtype, CNS WHO grade 4 (GBM) is the most aggressive primary malignant brain tumor in adults, with a median overall survival of approximately 15 months despite maximal surgical resection, radiotherapy, and chemotherapy with temozolomide. This therapeutic resistance is increasingly attributed to the...

Jia-Na Lei, Mei Lao, Zhuo-Na Ni et al. · 0 citations
Open access Sep 2026

KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer

Immunotherapy has emerged as a revolutionary therapeutic approach to treat cancer showing remarkable clinical responses. However, its efficacy in solid tumours such as prostate cancer (PCa) remains very limited due to a highly immunosuppressive tumour immune microenvironment (TIME) that hampers cytotoxic T cell infiltr...

Jon Peñarando, D. Willmann, Manuela Sum et al. · 0 citations
Open access Oct 2026

Macrophage- or neutrophil-expressed UPP1 drives tumor growth and immune suppression in the tumor microenvironment

Uridine phosphorylase 1 (UPP1) has recently emerged as a metabolic regulator with critical roles in tumor cell biology. However, its expression pattern and functional significance in nonmalignant components of the tumor microenvironment (TME) remain largely unexplored. Here, we performed a comprehensive pan-cancer sing...

Yin Li, Qin Ran, An-Ying Xiong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.